Dergiler / Diagnostic and Interventional Radiology / 2016 / Cilt: 22 - Sayı: 4

Feasibility of histogram analysis of susceptibility-weighted MRI for staging of liver fibrosis

Sayfa
301–307
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

CONCLUSION Magnetic resonance histogram analysis of SWI, particularly the variance, is promising for predicting advanced liver fibrosis and cirrhosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:PURPOSE We aimed to evaluate whether histogram analysis of susceptibility-weighted imaging (SWI) could quantify liver fibrosis grade in patients with chronic liver disease (CLD).
📊
Temel Bulgular & Veri:METHODS Fifty-three patients with CLD who underwent multi-echo SWI (TEs of 2.5, 5, and 10 ms) were included.
💡
Sonuç & Katkı:CONCLUSION Magnetic resonance histogram analysis of SWI, particularly the variance, is promising for predicting advanced liver fibrosis and cirrhosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

PURPOSE We aimed to evaluate whether histogram analysis of susceptibility-weighted imaging (SWI) could quantify liver fibrosis grade in patients with chronic liver disease (CLD). METHODS Fifty-three patients with CLD who underwent multi-echo SWI (TEs of 2.5, 5, and 10 ms) were included. Histogram analysis of SWI images were performed and mean, variance, skewness, kurtosis, and the 1st, 10th, 50th, 90th, and 99th percentiles were derived. Quantitative histogram parameters were compared. For significant parameters, further receiver operating characteristic (ROC) analyses were performed to evaluate the potential diagnostic performance for differentiating liver fibrosis stages. RESULTS The number of patients in each pathologic fibrosis grade was 7, 3, 5, 5, and 33 for F0, F1, F2, F3, and F4, respectively. The results of variance (TE: 10 ms), 90th percentile (TE: 10 ms), and 99th percentile (TE: 10 and 5 ms) in F0-F3 group were significantly lower than in F4 group, with areas under the ROC curves (AUCs) of 0.84 for variance and 0.70-0.73 for the 90th and 99th percentiles, respectively. The results of variance (TE: 10 and 5 ms), 99th percentile (TE: 10 ms), and skewness (TE: 2.5 and 5 ms) in F0-F2 group were smaller than those of F3/F4 group, with AUCs of 0.88 and 0.69 for variance (TE: 10 and 5 ms, respectively), 0.68 for 99th percentile (TE: 10 ms), and 0.73 and 0.68 for skewness (TE: 2.5 and 5 ms, respectively). CONCLUSION Magnetic resonance histogram analysis of SWI, particularly the variance, is promising for predicting advanced liver fibrosis and cirrhosis.

🔖

Bu Makaleye Atıf Yap

YANG, Z., LİANG, H., HU, X., HUANG, Y., DİNG, Y., YANG, S., ZENG, M., RAO, S. (2016). Feasibility of histogram analysis of susceptibility-weighted MRI for staging of liver fibrosis. Diagnostic and Interventional Radiology, Cilt: 22 - Sayı: 4, 301–307. https://ajindex.com/articles/200313

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol 2003; 38 (Suppl 1):S38-53. [CrossRef] Friedman SL, Bansal MB. Reversal of hepatic fibrosis--fact or fantasy? Hepatology 2006; 43:S82-88. [CrossRef] Fallowfield JA, Kendall TJ, Iredale JP. Reversal of fibrosis: no longer a pipe dream? Clin Liver Dis 2006; 10: 481-497. [CrossRef] Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50:1294-1306. [CrossRef] Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive biomarkers of liver fibrosis: clinical applications and future directions. Curr Patho- biol Rep 2014; 2:245-256. [CrossRef] Miyazaki S, Takasaki K, Yamamoto M, Tsugita M, Otsubo T. Liver regeneration and restoration of liver function after partial hepatectomy: the re- lation of fibrosis of the liver parenchyma. Hepa- togastroenterology 1999; 46:2919-2924.
  2. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49:1017-1044. [CrossRef] Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population based study includ- ing 4275 biopsies. Liver Int 2008; 28:705-712. [CrossRef] Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liv- er biopsy. An analysis of risk factors. Digestion 2003; 67:138-145. [CrossRef] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500. [CrossRef] Degos F, Perez P, Roche B, et al. Diagnostic accu- racy of FibroScan and comparison to liver fibro- sis biomarkers in chronic viral hepatitis: a multi- center prospective study (the FIBROSTIC study). J Hepatol 2010; 53:1013-1021. [CrossRef] Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and dif- fusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology 2012; 56:239-247. [CrossRef] Bonekamp S, Torbenson MS, Kamel IR. Diffu- sion-weighted magnetic resonance imaging for the staging of liver fibrosis. J Clin Gastroen- terol 2011; 45:885-892.[CrossRef] Fujimoto K, Tonan T, Azuma S, et al. Evaluation of the mean and entropy of apparent diffu- sion coefficient values in chronic hepatitis C: correlation with pathologic fibrosis stage and inflammatory activity grade. Radiology 2011; 258:739-748. [CrossRef] Do RK, Chandarana H, Felker E, et al. Diagno- sis of liver fibrosis and cirrhosis with diffu- sion-weighted imaging: value of normalized apparent diff